Chemotherapeutics of visceral leishmaniasis: present and future developments

S Sundar, A Singh - Parasitology, 2018 - cambridge.org
Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging
with few treatment options. Long duration of treatment and drug toxicity further limit the target …

Post kala-azar dermal leishmaniasis: A threat to elimination program

MR Gedda, B Singh, D Kumar, AK Singh… - PLoS Neglected …, 2020 - journals.plos.org
Leishmaniasis remains a public health concern around the world that primarily affects poor
folks of the developing world spanning across 98 countries with mortality of 0.2 million to 0.4 …

Recent advances in chemotherapeutics for leishmaniasis: Importance of the cellular biochemistry of the parasite and its molecular interaction with the host

R Singh, M Kashif, P Srivastava, PP Manna - Pathogens, 2023 - mdpi.com
Leishmaniasis, a category 1 neglected protozoan disease caused by a kinetoplastid
pathogen called Leishmania, is transmitted through dipteran insect vectors (phlebotomine …

Assessing the efficacy and safety of liposomal amphotericin B and miltefosine in combination for treatment of post kala-azar dermal leishmaniasis

V Ramesh, KK Dixit, N Sharma, R Singh… - The Journal of …, 2020 - academic.oup.com
Background No satisfactory canonical treatment is available for post-kala-azar dermal
leishmaniasis (PKDL), clinical sequela of visceral leishmaniasis. Confined treatment options …

Limitations of current chemotherapy and future of nanoformulation-based AmB delivery for visceral leishmaniasis—An updated review

P Kumar, P Kumar, N Singh, S Khajuria… - … in Bioengineering and …, 2022 - frontiersin.org
Visceral leishmaniasis (VL) is the most lethal of all leishmaniasis diseasesand the second
most common parasiticdisease after malaria and, still, categorized as a neglected tropical …

Synthesis and anti-leishmanial evaluation of 1-phenyl-2, 3, 4, 9-tetrahydro-1H-β-carboline derivatives against Leishmania infantum

P Ashok, S Chander, A Tejeria, L Garcia-Calvo… - European Journal of …, 2016 - Elsevier
In the present study, antileishmanial activity of sixteen novel series of tetrahydro-β-carboline
derivatives against transgenic infrared fluorescent Leishmania infantum strain has been …

Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the …

S Singh-Phulgenda, R Kumar, P Dahal… - PLOS Neglected …, 2024 - journals.plos.org
Background Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis which can occur
after successful treatment of visceral leishmaniasis (VL) and is a public health problem in VL …

Report of the fifth post-kala-azar dermal leishmaniasis consortium meeting, Colombo, Sri Lanka, 14–16 May 2018

EE Zijlstra, A Kumar, A Sharma, S Rijal, D Mondal… - 2020 - Springer
Abstract The 5th Post-Kala-Azar Dermal Leishmaniasis (PKDL) Consortium meeting brought
together PKDL experts from all endemic areas to review and discuss existing and new data …

Barriers to the effective management and prevention of post kala-azar dermal leishmaniasis (PKDL) in the Indian subcontinent

B Pal, S Kumari, M Kaur, P Wadhwa, K Murti… - Medical Journal Armed …, 2023 - Elsevier
Post kala-azar dermal leishmaniasis (PKDL) is a skin disease that usually occurs among
individuals with a past history of visceral leishmaniasis (VL). PKDL cases act as a reservoir …

Therapeutic modalities in post kala-azar dermal leishmaniasis: A systematic review of the effectiveness and safety of the treatment options

A Datta, I Podder, A Das, A Sil… - Indian Journal of …, 2021 - journals.lww.com
Post-kala-azar dermal Leishmaniasis (PKDL) is one of the important neglected tropical
diseases, which has a tremendous epidemiological significance, being the reservoir of kala …